Continuous proton pump inhibitor therapy and the associated risk of recurrent clostridium difficile infection

JAMA Internal Medicine

Volumn 175, Issue 5, 2015, Pages 784-791

  McDonald, Emily G ^a,b   Milligan, Jonathon ^c   Frenette, Charles ^a   Lee, Todd C ^a,b  

^a MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

^b MCGILL UNIVERSITY   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

METRONIDAZOLE; PROTON PUMP INHIBITOR; VANCOMYCIN; ANTIINFECTIVE AGENT;

AGED; ANTIBIOTIC THERAPY; ANTICOAGULANT THERAPY; ARTICLE; CANADA; CLOSTRIDIUM DIFFICILE INFECTION; COHORT ANALYSIS; CONTINUOUS INFUSION; DRUG REEXPOSURE; DRUG USE; DRUG WITHDRAWAL; EOSINOPHILIC ESOPHAGITIS; EVIDENCE BASED PRACTICE; FEMALE; GENERAL HOSPITAL; HEALTH CARE; HELICOBACTER INFECTION; HOSPITAL INFECTION; HUMAN; INFECTION RISK; LENGTH OF STAY; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; PEPTIC ULCER; PHYSICIAN; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; RECURRENT DISEASE; RECURRENT INFECTION; REFLUX ESOPHAGITIS; RETROSPECTIVE STUDY; RISK FACTOR; TREATMENT INDICATION; UPPER GASTROINTESTINAL BLEEDING; VERY ELDERLY; ADVERSE EFFECTS; AGE; CLASSIFICATION; CLOSTRIDIUM INFECTIONS; CROSS INFECTION; DRUG EFFECTS; INAPPROPRIATE PRESCRIBING; INCIDENCE; MIDDLE AGED; PATHOPHYSIOLOGY; PEPTOCLOSTRIDIUM DIFFICILE; PREVENTION AND CONTROL; PROCEDURES; SECONDARY PREVENTION; STATISTICS AND NUMERICAL DATA; TREATMENT WITHDRAWAL;

AGE FACTORS; AGED; ANTI-BACTERIAL AGENTS; CANADA; CLOSTRIDIUM DIFFICILE; CLOSTRIDIUM INFECTIONS; CROSS INFECTION; FEMALE; HUMANS; INAPPROPRIATE PRESCRIBING; INCIDENCE; LENGTH OF STAY; MALE; MIDDLE AGED; PROTON PUMP INHIBITORS; RETROSPECTIVE STUDIES; RISK FACTORS; SECONDARY PREVENTION; WITHHOLDING TREATMENT;

EID: 84929081231     PISSN: 21686106     EISSN: 21686114     Source Type: Journal    
DOI: 10.1001/jamainternmed.2015.42     Document Type: Article

References (37)

1. Polage CR, Solnick JV, Cohen SH. Nosocomial diarrhea: evaluation and treatment of causes other than Clostridium difficile. Clin Infect Dis. 2012;55(7): 982-989.
2. Zimlichman E, Henderson D, Tamir O, et al. Health care-associated infections: a meta-analysis of costs and financial impact on the US health care system. JAMA Intern Med. 2013;173(22): 2039-2046.
3. Kwok CS, Arthur AK, Anibueze CI, Singh S, Cavallazzi R, Loke YK. Risk of Clostridium difficile infection with acid suppressing drugs and antibiotics: meta-analysis. Am J Gastroenterol. 2012;107(7):1011-1019.
4. Drekonja DM, Butler M, MacDonald R, et al. Comparative effectiveness of Clostridium difficile treatments: a systematic review. Ann Intern Med. 2011;155(12):839-847.
5. Janarthanan S, Ditah I, Adler DG, Ehrinpreis MN. Clostridium difficile-associated diarrhea and proton pump inhibitor therapy: a meta-analysis. Am J Gastroenterol. 2012;107(7):1001-1010.
6. Deshpande A, Pant C, Pasupuleti V, et al. Association between proton pump inhibitor therapy and Clostridium difficile infection in a meta-analysis. Clin Gastroenterol Hepatol. 2012;10 (3):225-233.
7. Health Canada. Proton pump inhibitors (antacids): possible risk of Clostridium difficile-associated diarrhea. 2012. http://www.healthycanadians.gc.ca/recall-alert-rappel-avis/hc-sc/2012/13651a-eng.php. Accessed January 20, 2015.
8. US Food and Drug Administration. FDA Drug Safety Communication: Clostridium difficile-associated diarrhea can be associated with stomach acid drugs known as proton pump inhibitors (PPIs). 2012. http://www.fda.gov/drugs/drugsafety/ucm290510.htm. Accessed January 19, 2015.
9. US Food and Drug Administration. FDA Drug Safety Communication: possible increased risk of fractures of the hip, wrist, and spine with the use of proton pump inhibitors. 2012. http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm213206.htm. Accessed January 19, 2015.
10. Health Canada. Proton pump inhibitors: hypomagnesemia accompanied by hypocalcemia and hypokalemia. 2011. http://www.hc-sc.gc.ca/dhp-mps/medeff/bulletin/carn-bcei-v21n3-eng.php#-Proton-pump-inhibitors. Accessed January 19, 2015.
11. Health Canada. Plavix (blood thinner): new recommendations for use with PPIs (antacids). 2011. http://www.healthycanadians.gc.ca/recall-alert-rappel-avis/hc-sc/2011/13545a-eng.php. Accessed January 20, 2015.
12. Maggio M, Corsonello A. Harmful effects of proton pump inhibitors: discrepancies between observational studies and randomized clinical trials: reply. JAMA Intern Med. 2013;173(16): 1559-1560.
13. Zink DA, Pohlman M, Barnes M, Cannon ME. Long-term use of acid suppression started inappropriately during hospitalization. Aliment Pharmacol Ther. 2005;21(10):1203-1209.
14. Naunton M, Peterson GM, Bleasel MD. Overuse of proton pump inhibitors. J Clin Pharm Ther. 2000;25(5):333-340.
15. Freedberg DE, Salmasian H, Friedman C, Abrams JA. Proton pump inhibitors and risk for recurrent Clostridium difficile infection among inpatients. Am J Gastroenterol. 2013;108(11): 1794-1801.
16. Linsky A, Gupta K, Lawler EV, Fonda JR, Hermos JA. Proton pump inhibitors and risk for recurrent Clostridium difficile infection. Arch Intern Med. 2010;170(9):772-778.
17. Kim JW, Lee KL, Jeong JB, et al. Proton pump inhibitors as a risk factor for recurrence of Clostridium-difficile-associated diarrhea. World J Gastroenterol. 2010;16(28):3573-3577.
18. Cadle RM, Mansouri MD, Logan N, Kudva DR, Musher DM. Association of proton-pump inhibitors with outcomes in Clostridium difficile colitis. Am J Health Syst Pharm. 2007;64(22):2359-2363.
19. Cohen SH, Gerding DN, Johnson S, et al; Society for Healthcare Epidemiology of America; Infectious Diseases Society of America. Clinical practice guidelines for Clostridium difficile infection in adults: 2010 update by the Society for Healthcare Epidemiology of America (SHEA) and the Infectious Diseases Society of America (IDSA). Infect Control Hosp Epidemiol. 2010;31(5):431-455.
20. Wolbers M, Koller MT, Stel VS, et al. Competing risks analyses: objectives and approaches. Eur Heart J. 2014;35(42):2936-2941.
21. Wolkewitz M, Cooper BS, Bonten MJ, Barnett AG, Schumacher M. Interpreting and comparing risks in the presence of competing events. BMJ. 2014;349:g5060.
22. Fine JP, Gray RJ. A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc. 1999;94(446):496-509.
23. White IR, Royston P, Wood AM. Multiple imputation using chained equations: issues and guidance for practice. Stat Med. 2011;30(4): 377-399.
24. Sung JJ, Chung SC, Ling TK, et al. Antibacterial treatment of gastric ulcers associated with Helicobacter pylori. N Engl J Med. 1995;332(3): 139-142.
25. Lau JY, Sung JJ, Lee KK, et al. Effect of intravenous omeprazole on recurrent bleeding after endoscopic treatment of bleeding peptic ulcers. N Engl J Med. 2000;343(5):310-316.
26. Chey WD, Wong BC; Practice Parameters Committee of the American College of Gastroenterology. American College of Gastroenterology guideline on the management of Helicobacter pylori infection. Am J Gastroenterol. 2007;102(8):1808-1825.
27. Lanza FL, Chan FK, Quigley EM; Practice Parameters Committee of the American College of Gastroenterology. Guidelines for prevention of NSAID-related ulcer complications. Am J Gastroenterol. 2009;104(3):728-738.
28. Rostom A, Moayyedi P, Hunt R; Canadian Association of Gastroenterology Consensus Group. Canadian consensus guidelines on long-term nonsteroidal anti-inflammatory drug therapy and the need for gastroprotection: benefits versus risks. Aliment Pharmacol Ther. 2009;29(5): 481-496.
29. van Vliet EP, Steyerberg EW, Otten HJ, et al. The effects of guideline implementation for proton pump inhibitor prescription on two pulmonary medicine wards. Aliment Pharmacol Ther. 2009;29 (2):213-221.
30. Lai KC, Lam SK, Chu KM, et al. Lansoprazole for the prevention of recurrences of ulcer complications from long-term low-dose aspirin use. N Engl J Med. 2002;346(26):2033-2038.
31. McFarland LV, Surawicz CM, Rubin M, Fekety R, Elmer GW, Greenberg RN. Recurrent Clostridium difficile disease: epidemiology and clinical characteristics. Infect Control Hosp Epidemiol. 1999; 20(1):43-50.
32. Pathak R, Enuh HA, Patel A, Wickremesinghe P. Treatment of relapsing Clostridium difficile infection using fecal microbiota transplantation. Clin Exp Gastroenterol. 2013;7:1-6.
33. McFarland LV. Alternative treatments for Clostridium difficile disease: what really works? J Med Microbiol. 2005;54(pt 2):101-111.
34. D'Agostino RB Sr, Collins SH, Pencina KM, Kean Y, Gorbach S. Risk estimation for recurrent Clostridium difficile infection based on clinical factors. Clin Infect Dis. 2014;58(10):1386-1393.
35. Louie TJ, Miller MA, Mullane KM, et al; OPT-80-003 Clinical Study Group. Fidaxomicin versus vancomycin for Clostridium difficile infection. N Engl J Med. 2011;364(5):422-431.
36. van Nood E, Vrieze A, Nieuwdorp M, et al. Duodenal infusion of donor feces for recurrent Clostridium difficile. N Engl J Med. 2013;368(5): 407-415.
37. Amir I, Konikoff FM, Oppenheim M, Gophna U, Half EE. Gastric microbiota is altered in oesophagitis and Barrett's oesophagus and further modified by proton pump inhibitors. Environ Microbiol. 2014;16(9):2905-2914.